NCT03436472 is a NA clinical trial of dexmedetomidine in Aged, sponsored by Peking University First Hospital.

Who is sponsoring NCT03436472?

NCT03436472 is sponsored by Peking University First Hospital.

What drugs are being tested in NCT03436472?

Interventions in NCT03436472: dexmedetomidine, placebo.

What condition does NCT03436472 study?

NCT03436472 studies Aged, Operative, Delirium, Dexmedetomidine, Mortality, Long-term Survivors.

Is NCT03436472 still recruiting?

NCT03436472 is currently completed. Last updated 21 June 2019.

Last reviewed 2019-06-21 · How we verify

NCT03436472

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dexmedetomidine and 5-year Outcome in Elderly Patients After Surgery

Completed NA Last updated 21 June 2019

What this trial tests

NA trial testing dexmedetomidine in Aged in 700 participants. Completed in 1 April 2019.

Timeline

1 June 2017

Primary endpoint
8 January 2019

1 April 2019

Quick facts

Lead sponsor	Peking University First Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	700
Start date	1 June 2017
Primary completion	8 January 2019
Estimated completion	1 April 2019
Sites	1 location across China

Drugs / interventions tested

dexmedetomidine (dexmedetomidine) — full drug profile →
placebo

Conditions studied

Aged — all drugs for Aged →
Operative — all drugs for Operative →
Delirium — all drugs for Delirium →
Dexmedetomidine — all drugs for Dexmedetomidine →

Sponsor

Peking University First Hospital

Who can join

Adults 65 to 90, any sex, with Aged or Operative. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Delirium is a frequent postoperative complication. Its occurrence is associated with worse long-term outcomes. In a previous randomized controlled trial, prophylactic low-dose dexmedetomidine infusion during the early postoperative period decreased the incidence of delirium in elderly patients after surgery. The purpose of this 5-year follow-up study is to evaluate whether prophylactic low-dose dexmedetomidine infusion can improve the 5-year outcomes in elderly patients recruited in the previous randomized controlled trial.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of dexmedetomidine

Trials testing the same drug.

NCT06853431 — Determination of ED50 and ED95 With Clinical Efficacy of Intranasal Dexmedetomidine Combined With Esketamine for Preoper · Phase 4 · recruiting
NCT06702488 — Dexmedetomidine and Magnesium Sulfate in the Reduction Cognitive Dysfunction in Geriatrics · Phase 1 · recruiting
NCT06636578 — Dexmedetomidine Ropivacaine Versus Plain Ropivacaine in Bilateral Pectoralis Nerve (PECS) Block · Phase 4 · recruiting
NCT07510217 — ERAS Approach for Post-Craniotomy Headache and Psychological Recovery · Phase 2 · completed
NCT06498700 — Intraoperative Subanesthetic Ketamine Versus Dexmedetomidine Infusion for Prevention of Post-traumatic Stress Disorder A · NA · enrolling by invitation

Other recruiting trials for Aged

Currently open trials in the same condition.

NCT07481851 — Skin Conductance for Predicting Spinal Anesthesia-Induced Hypotension in Geriatric Urologic Oncology Patients · recruiting
NCT07358338 — Application of Device-based Training to Improve Postural Control in Older Adults With CCI · NA · active not recruiting
NCT06901167 — Evaluation of a Residential In-Reach Program in Regional and Rural Australia · NA · recruiting
NCT06973460 — Robotic-Assisted System in Enhancing Balance, Postural Stability, Functional Gait and Fall Efficacy in Older Adults · NA · recruiting
NCT06929351 — Effect of Otago Exercise Program in Comparison With Dual Task Training on Balance and Postural Control in Elderly Popula · NA · active not recruiting

Other Peking University First Hospital trials

Trials by the same sponsor.

NCT07498907 — Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelia · Phase 2 · not yet recruiting
NCT07517276 — TUDCA in High-Risk Lactating Mothers Identified by Early Postpartum Milk Hydrophobicity Index · Phase 2 · not yet recruiting
NCT07504939 — Multimodal Kidney-Sparing Strategy for High-Risk Upper Tract Urothelial Carcinoma · not yet recruiting
NCT07464119 — A Clinical Study of iPSC-Derived Islet Cells for Diabetes Mellitus Therapy · NA · not yet recruiting
NCT07460843 — Comparison of TB+PB and TB+6SB for Prostate Cancer Diagnosis · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03436472 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University First Hospital
Last refreshed: 21 June 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03436472.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing